Skip to main content
Journal cover image

Micafungin: the US perspective.

Publication ,  Journal Article
Zaas, AK; Steinbach, WJ
Published in: Expert Rev Anti Infect Ther
April 2005

Invasive fungal infections cause considerable morbidity and mortality in nosocomial settings and amongst immunocompromised hosts. Invasive candidiasis and aspergillosis remain the most common invasive fungal infections, with Candida spp. constituting the fourth most common bloodstream infection in the USA. Currently available antifungal therapies include the polyene, antimetabolite, allylamine, azole and echinocandin drug classes. Micafungin, approved in March 2005 by the Food and Drug Administration for use in the USA, has shown safety and efficacy for the treatment of candidiasis and aspergillosis in clinical trials in Japan, Europe and South Africa. Micafungin holds promise as a first-line treatment option for candidiasis, as well as prophylaxis against invasive fungal infections during periods of neutropenia in high-risk patients.

Duke Scholars

Published In

Expert Rev Anti Infect Ther

DOI

EISSN

1744-8336

Publication Date

April 2005

Volume

3

Issue

2

Start / End Page

183 / 190

Location

England

Related Subject Headings

  • Safety
  • Peptides, Cyclic
  • Mycoses
  • Microbiology
  • Micafungin
  • Lipoproteins
  • Lipopeptides
  • Humans
  • Echinocandins
  • Clinical Trials as Topic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zaas, A. K., & Steinbach, W. J. (2005). Micafungin: the US perspective. Expert Rev Anti Infect Ther, 3(2), 183–190. https://doi.org/10.1586/14787210.3.2.183
Zaas, Aimee K., and William J. Steinbach. “Micafungin: the US perspective.Expert Rev Anti Infect Ther 3, no. 2 (April 2005): 183–90. https://doi.org/10.1586/14787210.3.2.183.
Zaas AK, Steinbach WJ. Micafungin: the US perspective. Expert Rev Anti Infect Ther. 2005 Apr;3(2):183–90.
Zaas, Aimee K., and William J. Steinbach. “Micafungin: the US perspective.Expert Rev Anti Infect Ther, vol. 3, no. 2, Apr. 2005, pp. 183–90. Pubmed, doi:10.1586/14787210.3.2.183.
Zaas AK, Steinbach WJ. Micafungin: the US perspective. Expert Rev Anti Infect Ther. 2005 Apr;3(2):183–190.
Journal cover image

Published In

Expert Rev Anti Infect Ther

DOI

EISSN

1744-8336

Publication Date

April 2005

Volume

3

Issue

2

Start / End Page

183 / 190

Location

England

Related Subject Headings

  • Safety
  • Peptides, Cyclic
  • Mycoses
  • Microbiology
  • Micafungin
  • Lipoproteins
  • Lipopeptides
  • Humans
  • Echinocandins
  • Clinical Trials as Topic